Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options.

118 , 119 In a Phase II study in patients with predominantly negative symptoms, the addition of bitopertin 10 mg or 30 mg once daily to a stable regimen of antipsychotic therapy significantly improved the PANSS-NSFS after 8 weeks of treatment (per protocol population) with a trend toward significance in the ITT (intent-to-treat) population. 80 The SearchLyte Phase III program studying adjunctive bitopertin for the treatment of symptoms of schizophrenia is composed of six trials; three in patients with predominant negative symptoms ( NCT01192906 , 120 NCT01192880 , 121 NCT01192867 122 ) and three in patients with suboptimally controlled symptoms ( NCT01235559 , 123 NCT01235585 , 124 NCT01235520 125 ).

also in 3,729 other papers